BridgeBio Pharma (BBIO)
(Delayed Data from NSDQ)
$26.74 USD
-0.09 (-0.34%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $26.72 -0.02 (-0.07%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth D Momentum D VGM
Price, Consensus and EPS Surprise
BBIO 26.74 -0.09(-0.34%)
Will BBIO be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for BBIO based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for BBIO
BridgeBio Pharma (BBIO) Reports Q2 Loss, Misses Revenue Estimates
Viatris' (VTRS) Q1 Earnings & Sales Lag Estimates, Stock Down
BBIO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Dr. Reddy's (RDY) Q4 Earnings Top, North America Sales Grow
Will BridgeBio Pharma (BBIO) Report Negative Q1 Earnings? What You Should Know
Bayer (BAYRY) Banks on Pipeline Progress Amid Challenges
Other News for BBIO
First Week of January 2027 Options Trading For BridgeBio Pharma (BBIO)
BridgeBio achondroplasia asset infigratinib nabs FDA Breakthrough Therapy status
BioMarin in spotlight as data suggests Ascendisâ???? candidate could rival Voxzogo
BridgeBio Announces Infigratinib Is the First Ever Investigational Therapeutic Option for Achondroplasia to Be Awarded Breakthrough Therapy Designation by the FDA
BioMarin price target lowered by $28 at Truist, here's why